Royalty Report: Drugs, Disease, Therapeutic – Collection: 279369

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 15

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 15

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Diagnostic
  • Drug Discovery
  • Viral Infection
  • Antibiotic
  • Genome
  • Molecular
  • Proteins
  • Pharmaceuticals
  • Cancer
  • DNA
  • HIV / AIDs
  • Assay
  • Test/Monitoring
  • Vaccine

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 279369

License Grant
Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under Licensor Technology to Develop, make, have made, use, sell, have sold, offer for sale and import Compounds and Licensed Products in the Field in the Territory.

This agreement includes a non-exclusive grant back to Licensor.

License Property
Licensor has certain proprietary technology in compounds for the prevention and treatment of chronic hepatitis C infection.

The patents include Substituted Aryl Acylthioureas and Related Compounds Inhibitors of Viral Replication;
Heteroaryl Substituted Thioureas Inhibitors of Viral Replication;   Substituted Aryl Acylthioureas and Related Compounds Inhibitors of Viral Replication;  and, Substituted Arylthiourea Derivates Useful as Inhibitors of Viral Replication.

Compound means each of the following
—  inhibitors of HCV replication,  
—  any compound made pursuant to the Research Program with utility in the HCV Field or proven at a later date to have utility in the HCV Field; or,
—  any additional small molecules that are identified by either Party at any time prior to the end of the term of the Agreement, which can reasonably be demonstrated to inhibit HCV replication in replicon containing cells with a primary mechanism that results in abnormal processing of HCV proteins via HCV NS3 protease.

Field of Use
The Field means all human and animal therapeutic, diagnostic, and prophylactic uses, including, without limitation, the treatment, prevention and prophylaxis of hepatitis C viral infections.

HCV Field means the treatment of chronic hepatitis C viral infections in humans.

IPSCIO Record ID: 275842

License Grant
For the Research and Development License Grant, Licensor grants to Licensee and to its wholly owned subsidiaries and to those of its Affiliates conducting research and development activities at the Licensee Facilities and to other of its Affiliates approved in writing by Licensor, a non-transferable, non-exclusive license, without the right to sublicense under the Licensor Patent Rights, to use Licensed Compositions and Licensed Methods in the Research and Development Field at a designated Licensee Facility in the Licensed Territory during the Research and Development Term and to make, have made, use, have used, sell, have sold, import, and export Identified Products during the term of this Agreement.
License Property
Licensor has developed certain intellectual property rights with respect to Hepatitis C Virus (HCV) which relate to the HCV genome and encoded proteins.

Patent/Application No] [Country][5,714.596] [US][6,074,816] [US][5,712,088] [US][6,027,729] [US][5,863,719] [US][5,371,017] [US][5,585,258] [US][5,597,691] [US][6,194,140] [US][5,712,145] [US][5,885,799] [US][5,989,905] [US][6,472,180] [US][09/884455] [US][09/884456] [US][10/232643] [US][6,096,541] [US][5,679,342] [US][5,968,775] [US]

Field of Use
Licensee is engaged in the research and development of small molecule inhibitors of the HCV genome and encoded proteins and related therapeutics for the treatment of HCV infection.

IPSCIO Record ID: 209534

License Grant
For Licensed Products,  Licensor grants the Swiss Licensee an exclusive, even as to Licensor, license under the Licensor Patent Rights and Know-How, with the right to grant sublicenses, to make, use, sell, offer for sale, import and export Licensed Products for all uses in the Territory.

For HCV Activity Compounds, Licensor grants an exclusive, even as to Licensor, license under the Licensor Patent Rights to make, use, offer for sale, import and export any HCV Activity Compounds solely within the Field in the Territory.

Licensor grants a non-exclusive license under any such patents to develop, make, have made, import, export, use, offer for sale and sell Licensed Products for all uses in the Territory.

For research, Licensor grants a non-exclusive license under its patents, trademarks and other intellectual property only to the extent necessary to carry out Licensees obligations and responsibilities under the Research Program and to develop and commercialize a Licensed Product.

Licensee, its Affiliates and sublicensees shall be free to use and to register in any trademark office worldwide any Trademark for use with Licensed Products they desire in their sole discretion.

License Property
The Licensed Product means anything containing or derived from a Candidate Compound.  The Candidate Compound means chemical entities designed or identified by Licensor as of the Effective Date or pursuant to the Research Program that are inhibitors of at least one (1) protease of the Hepatitis C virus.

HCV Activity Compounds means Candidate Compounds, other than Licensed Products or Back-Up Compounds, or Non-Collaboration Compounds meeting the HCV Activity Criteria set forth.

The patents are those filed to protect Licensor Inventions or interest in Joint Inventions, or otherwise filed to protect either a transition state-based inhibitor of the NS3 protease of the Hepatitis C virus existing within Licensor Know-How as of the Effective Date or an inhibitor of the Hepatitis C viral proteases within Licensor KnowHow arising from the Research Program.

Field of Use
This agreement is for the treatment or prevention of Hepatitis C infections in humans and/or animals.

IPSCIO Record ID: 356267

License Grant
For the Development License, Licensor grants to Janssen an exclusive, worldwide license, with the right to sublicense, under the Licensor Background IP and Licensors rights in the Development Program IP, to Develop and have Developed Licensor Single APIs and Licensed Products in the field, and to make and Manufacture, have made and Manufactured, use, have used, and import Licensor Single APIs and Licensed Products for such purposes.

For the Commercialization License, Licensor grants an exclusive, worldwide license, with the right to sublicense, under the Licensor Background IP and Licensors rights in the Development Program IP, to Commercialize and have Commercialized, offer for sale and sell, and have offered for sale and sold. Licensor Single APls and Licensed Products for use in the Field. and to make. have made. use, have used. and import Licensor Single APls and Licensed Products for such purposes.

This agreement includes a non-exclusive grant back to Licensor from Licensee.

License Property
Licensor possesses certain information, materials, and intellectual property rights relating to certain drug substances in clinical development for treating hepatitis C virus (HCV) infection, including the compound known as ACH-3102, which is an HCV NS5A inhibitor, the compound known as ACH-3422, which is an HCV NS5B inhibitor, and the compound known as sovaprevir, which is an HCV NS3/4A inhibitor.

Licensors Single API means an ACH NS3/4A API, ACH NS5A API, or ACH NS5B API.

The patents include but are not limited to
4-amino-4-oxobutanoyl peptides as inhibitors of HCV Replication, and,
Novel processes for producing sovaprevir.

Field of Use
The Field of use means the prevention, treatment, and/or diagnosis of any and all human disorders or medical conditions, including the treatment of hepatitis C virus (HCV) infection.

IPSCIO Record ID: 203459

License Grant
Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under Licensors interest in Collaboration Patents, and Collaboration Know-How, in each case solely to develop, make, have made, use, sell, have sold, offer for sale and import Products in the Field in the Territory; provided, however, that Licensor retains such rights under Collaboration Technology as are necessary to perform its obligations under the Research Program.

This agreement also includes Non-Exclusive Cross-Licenses where each Party hereby grants to the other Party a non-exclusive, royalty-free license, without the right to sub-license
(i) under such Partys interest in Collaboration Know-How for the manufacture or formulation of products other than Products, including 'cocktail' and other Combination Products; and
(ii) under such Partys interest in Collaboration Know-How, solely to conduct research in the HCV Field in the Territory.

License Property
Licensor has a research program for the discovery and optimization of nucleoside inhibitors of the NS5b polymerase in hepatitis C virus.

The Collaboration Compound shall mean a Nucleoside that satisfies the chemical and technical requirements set forth, and its Related Compounds and which
(a) is or was synthesized by or for Licensor on or before the Effective Date or during the Research Program Term; or
(b) is a Related Compound to a Collaboration Compound disclosed by Licensor to Licensee pursuant to Identification and Contribution of Collaboration Compounds and which is synthesized by or for Licensee after the Effective Date.

The Collaboration Compound Products shall mean any preparations in final form, bulk form or other form containing as an active pharmaceutical ingredient one or more Selected Compounds.

Field of Use
The Field shall mean all human and animal therapeutic, diagnostic, and prophylactic uses, including, without limitation, the treatment, prevention and prophylaxis of hepatitis C viral infections.

The HCV Field shall mean the treatment of chronic hepatitis C viral infections in humans.

The Collaboration Compound Products are for sale by prescription, over-the-counter or any other method, including without limitation any Combination Product.

IPSCIO Record ID: 303948

License Grant
Licensor assigns all of Licensor’s right, title and interest in the Assigned Patents and Assigned Know-How.

Licensor grants a non- exclusive, revocable, sublicenseable, nontransferable license, under the Licensed Know- How to Research, Develop, Manufacture, have Manufactured, use, keep, sell, offer for sale, import, export and Commercialize the Assigned Compounds and Products in the Field of Use in the Territory during the Term.

This agreement includes an exclusive grant back to Licensor.

License Property
Licensor owns rights to the proprietary compounds identified as VX-222 and VX-497.

VX-222 is an investigational HCV (Hepatitis C Virus) polymerase inhibitor.  Treatment with VX-222 resulted in mean reductions in plasma HCV RNA of greater than 3 log10.

VX-497, or merimepodib, is a drug for autoimmune diseases.

Field of Use
The field of use is the field of anti-infectives and anti-virals and the diagnosis, treatment, or prevention thereof.

VX-222 is for the oral Treatment of Hepatitis C.  VX-497, or merimepodib, is an oral treatment for HCV (Hepatitis C Virus) infection.  This agreement Field does not limit the use to HCV, but does limit the use to Anti-infectives and Anti-virals.

IPSCIO Record ID: 316064

License Grant
This amendment, updates the Licensees name to its successor, and, amends milestones and royalties.   In the original agreement,  Licensor grants a non- exclusive, revocable, sublicenseable, nontransferable license, under the Licensed Know- How to Research, Develop, Manufacture, have Manufactured, use, keep, sell, offer for sale, import, export and Commercialize the Assigned Compounds and Products in the Field of Use in the Territory during the Term.  The original agreement includes an exclusive grant back to Licensor.
License Property
The original agreement states Licensor owns rights to the proprietary compounds identified as VX-222 and VX-497.

VX-222 is an investigational HCV (Hepatitis C Virus) polymerase inhibitor.  Treatment with VX-222 resulted in mean reductions in plasma HCV RNA of greater than 3 log10.

VX-497, or merimepodib, is a drug for autoimmune diseases.

Field of Use
The original agreement states the field of use is the field of anti-infectives and anti-virals and the diagnosis, treatment, or prevention thereof.

VX-222 is for the oral Treatment of Hepatitis C.  VX-497, or merimepodib, is an oral treatment for HCV (Hepatitis C Virus) infection.  This agreement Field does not limit the use to HCV, but does limit the use to Anti-infectives and Anti-virals.

IPSCIO Record ID: 203549

License Grant
For the technology, Licensor grants the Licensee of Bermuda, an exclusive, even as to Licensor, worldwide, sub-licensable license, under the Licensors Technology, to develop, make, have made, use, sell, have sold, offer for sale and import the Licensors Compounds and Products in the Primary Fields; and to develop, make and have made the Licensors Compounds and Products in the ID Field, but without any right to sell or commercialize in the ID Field. Licensee may sublicense the rights granted.

Each Party hereby grants to the other Party a non-exclusive, non-sublicensable (except to Affiliates) license to its Patent Rights and Know-How solely to the extent necessary to permit such other Party to perform its responsibilities relating to the Anadys Compound or Product under the Development Plan during the term of this Agreement.

License Property
The product is any product incorporating or comprising the Lead Compound or any other Licensors Compound in finished dosage pharmaceutical form, including, in each case, all formulations and modes of administration thereof, the development, manufacture, sale or use of such Lead Compound or other Licensor Compound would, but for the license granted hereunder, infringe the Licensor Patent Rights or incorporates or embodies Licensor Know-How.

The licensing and co-development agreement is for the development and potential commercialization of ANA975 and potentially additional Toll-Like Receptor (“TLR7”) oral prodrugs for chronic hepatitis C virus (“HCV”) and hepatitis B virus (“HBV”) infections, as well as other potential infectious disease indications.

ANA975, a 5-amino-3-ß -D-ribofuranosyl-3H-thiazolo[4,5-d]pyrimidin-2-one derivative, was synthesized in the search of an oral prodrug of isatoribine, a small molecule toll-like receptor 7 (TLR-7) agonist.

Toll-like receptor 7, also known as TLR7, is a protein that in humans is encoded by the TLR7 gene.

Field of Use
The primary field is the HCV Field and HBV Field. Primary field shall mean either the HCV Field or the HBV Field, as applicable.

ID field means the treatment, diagnosis or prevention of infectious diseases outside of the Primary Fields.

HBV field means the treatment, diagnosis or prevention of hepatitis B virus (HBV).
HCV field means the treatment, diagnosis or prevention of hepatitis C virus (HCV).

IPSCIO Record ID: 239036

License Grant
This agreement is a research collaboration to apply Licensor Technology to Licensee HCV Compounds to develop the Collaboration Compounds.

For the License under Prior Technology and Collaboration Technology, Licensor grants to Merck an exclusive, even as to Licensor, license, with the right to sublicense, under Licensors interest in Prior Technology and Collaboration Technology solely to perform Licensees obligations under the Research Program during the Research Program Term and to develop, make, have made, use, sell, have sold, offer for sale and import Collaboration Compounds and Products in the Field in the Territory.

For the License under Licensor Technology, Licensor grants a non-exclusive license, with the right to sublicense as described below, under Licensors interest in Licensor Technology solely to perform Licensees obligations under the Research Program during the Research Program Term and to develop, make, have made, use, sell, have sold, offer for sale and import Collaboration Compounds and Products in the Field in the Territory.

For the Limited License Grant, Licensor grants, effective at the time such determination is made, to the extent Licensor is then legally able to do so, a non-exclusive license, including the right to sublicense as described below, under the HCV Claims solely to develop, make, have made, use, sell, offer for sale, have sold or import Collaboration Compound(s) and Product(s) in the Field in the Territory.

License Property
Licensor has developed Licensor Technology for the discovery and optimization of liver targeted compounds.

Licensor technology, know-how and patents relate to HepDirect Technology.

Field of Use
The Field shall mean the treatment of hepatitis C viral infections in humans.

IPSCIO Record ID: 253

License Grant
Licensor grants Swiss Licensee a worldwide, sole and exclusive right and license, with the right to sublicense, to make and have made, use, offer for sale, import and sell Compounds and Products under the Licensee Proprietary Rights and Licensees’ part of the Joint Patents.
License Property
The Parties have previously entered into (a) a Development and License Agreement (including its Appendices) dated as of the 1st day of July 1999, as amended by the Amendment to the Development and License Agreement (DLA First Amendment) executed July 12, 2004 and rescinded and voided ab initio on July 12, 2004 by the Rescission of the Amendment to the Development and License Agreement (Rescission) and the Letter of Amendment (DLA Second Amendment) effective September 20, 2005.

Product relates to brand name Fuzeon® in indications other than the treatment of HIV.  Fuzeon was developed in collaboration with the Licensee, and is our only currently marketed product.  Fuzeon, which is administered by subcutaneous injection, has been shown to inhibit HIV viral fusion with host cells by blocking the conformational rearrangement of an HIV protein called gp41.  The FDA approved the use of Fuzeon in combination with other anti-HIV drugs for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing anti-HIV therapy.

Date U.S. Pat. No. 5,464,933 11/7/95 Synthetic Peptide Inhibitors of HIV Transmission 6/7/2013
U.S. Patent No. 6,133,418 10/17/00 Synthetic Peptide Inhibitors of HIV Transmission 11/17/2014
U.S. Patent No. 6,475,491 11/5/02 Treatment of HIV and Other Viral Infections Using Combinatorial Therapy 6/7/2015
U.S. Patent No. 6,861,059 3/1/05 Methods and Compositions for Treatment of HIV-1 Infection Using Antiviral Compounds in Simultaneous or Sequential Combinations 9/9/2015
Canadian Patent No. 2,224,008 8/18/09 Treatment of HIV and Other Viral Infections Using Combinatorial Therapy 6/6/2016
U.S. Patent No. 6,281,331 8/28/01 Methods and Compositions for Peptide Synthesis 3/23/2018
U.S. Patent No. 6,015,881 1/18/00 Methods and Compositions for Peptide Synthesis 3/23/2018
U.S. Patent No. 6,824,783 11/30/04 Methods for Inhibition of Membrane Fusion-Associated Events, Including HIV Transmission 11/30/2021

Field of Use
Fusion inhibitors prevent viral fusion, a complex process by which viruses attach to, penetrate and infect host cells. If a virus cannot enter a host cell, the virus cannot replicate. By inhibiting the fusion process of particular types of viruses, like the Human Immunodeficiency Virus, the Licensor's first and only commercial product, Fuzeon (whose generic name is enfuvirtide, originally known as T-20), offers a novel mechanism of action to treat and potentially prevent the transmission of HIV.

IPSCIO Record ID: 291164

License Grant
The licenses granted include the right of each licensee to use its Affiliates in exercising such rights and carrying out its obligations under this Agreement.

Licensor hereby grants to Licensee the exclusive (except as to Licensor to permit it conduct its Co-Funded Development and/or Co-Commercialization activities and those activities under the ITMN-191 Transition Plan hereunder) license under the Licensor Know-How and Licensor Patent Rights and under Licensor’s rights in Joint Know-How and Joint Patent Rights to develop, make, have made, use, import, export, offer for sale and sell Licensed Compounds and Products in the Territory.

License Property
ITMN-191 shall mean that Macrocycle identified within Licensee as ITMN-191, together with its salts and esters, which is hereby designated a Licensed Compound.

Macrocycle shall mean any cyclic macromolecule in the Field containing a substituted proline moiety and optional Pl and P3 groups as part of the backbone ring and supporting the attachment of Pl and P4 groups.

Licensee Patent Rights shall mean any and all patents and patent applications in the Field in the Territory which are Controlled by Licensor during the term of this Agreement which Cover any activity permitted under this Agreement, all to the extent that the subject matter claimed therein is used in the course of performing any activity permitted under this Agreement, including, but not limited to, the making, using, selling, offering to sell, exporting or importing Lead Compound, Licensed Compounds, Products, Passed Compounds or Reverted Compounds. For the purposes of this Agreement, “patents and patent applications” shall be deemed to include certificates of invention and applications for certificates of invention, as well as divisions, continuations, continuations-in-part, reissues, renewals, extensions, supplementary protection certificates, and the like of any such patents and patent applications and foreign equivalents thereof.

Joint Patent Rights shall mean any and all patents and patent applications in the Field in the Territory which are invented jointly during the term of this Agreement by employees of both Parties according to the U.S. laws pertaining to joint inventorship. For the purposes of this Agreement, “patents and patent applications” shall be deemed to include certificates of invention and applications for certificates of invention, as well as divisions, continuations, continuations-in-part, reissues, renewals, extensions, supplementary protection certificates, and the like of any such patents and patent applications and foreign equivalents thereof.

Licensed Compound shall mean (a) ITMN-191 and (b) Collaboration Compounds properly included by Licensee as Licensed Compounds; provided however, Licensee may substitute a Lead Compound for an existing Licensed Compound as set forth in this Agreement; provided further there shall not be more than two (2) Licensed Compounds at any time during the Term unless Licensee shall have exercised its option to expand the number of Licensed Compounds pursuant to this agreement.

Product(s) shall mean any pharmaceutical preparation containing a Licensed Compound for any and all uses in humans, including any Combination Product.

Field of Use
Field shall mean the treatment and/or prevention of acute or chronic HCV infection in humans by administering a compound whose mechanism of clinical activity results solely from  binding to and inhibiting the serine protease active site of HCV NS3/4A.

Hepatitis C virus (HCV) is a viral infection that causes liver inflammation, sometimes leading to serious liver damage.

IPSCIO Record ID: 243433

License Grant
For the Licensed IP Rights, the Italian Licensor grants an exclusive license under the Licensed IP Rights to conduct research and to develop, make, have made, use, offer for sale, sell and import Products in the Territory for use in the Field, and, Licensor grants a non-exclusive license under any patent, know-how or other intellectual property rights Controlled by Licensor to research and to develop, make, have made, use, offer for sale, sell and import any diagnostic product for one or more of the Exclusive Targets.
License Property
Product(s) shall mean any product that incorporates one or both of the APls and if made, used, sold, offered for sale or imported absent the license granted hereunder would infringe a Valid Claim, or that otherwise uses or incorporates the Licensor Know-How.

The patent is for Substituted Indazole Derivatives Active as Kinase Inhibitors.

RXDX-103 is an inhibitor of the cell division cycle 7-related (Cdc7) protein kinase, and RXDX-104 is a program to identify a highly selective inhibitor of the rearranged during transfection (RET) tyrosine kinase. Each of these programs is in preclinical development for the potential treatment of multiple cancers.

Loss of cell cycle control is a hallmark of cancer, and interfering with the DNA replication process is a proven strategy for cancer therapy. Currently available chemotherapies, such as anti-metabolites, topoisomerase inhibitors, and crosslinking and intercalating agents, classically take a broad-based approach to inhibiting the elongation step of DNA replication. This strategy has led to successful treatment outcomes, but off-target effects can lead to dose-limiting toxicity. Cdc7 is a serine/threonine protein kinase essential for the initiation step of DNA replication during the synthesis (S) phase.

Field of Use
The Field shall mean all fields of use, including without limitation the diagnosis, prevention or treatment of any disease, state or condition in humans or other animals.

Licensee has capabilities in the development of oncology products.

IPSCIO Record ID: 289184

License Grant
The University Foundation grants to Licensee the exclusive right and license to make, have made, use, import, offer for sale, and sell in the Territory, Licensed Products during the term of this Agreement including Licensee’s right to grant sublicenses.

The license granted is subject to a reserved, non-exclusive license of Foundation, transferable to University and its not-for-profit academic collaborators, to practice the Licensed Patents in the Field, only for the purpose of non-commercial scientific inquiry, academic research, and education.

License Property
Licensed Product means any compound, product, service, or process in the Field, the manufacture, use, or sale of which, but for the license granted herein, would infringe at least one Valid Claim.

Licensed Patents means (i) the patent applications listed, (ii) the United States patents that may issue from the patent applications listed and from divisionals and continuations and continuations-in-part of such United States patents and patent applications, (iii) all foreign counterparts of such patent applications, and all patents that issue thereon anywhere in the world, including reexamined and reissued patents. Licensed Patents shall also mean any patent application having claims in the Field directed to an invention made in the laboratory of Dr. Vasu Nair six months or less prior to the Effective date, and (iv) with respect to the matters described in clauses (i), (ii) and (iii) above, all provisionals, renewals, re-examinations, patents of addition, supplementary protection certificates, extensions, restorations of patent terms, letters of patent, registration or confirmation patents and reissues of such patents or patent applications.

7,250,421 – Diketo acids with nucleobase scaffolds anti-HIV replication inhibitors targeted at HIV integrase

Indication shall mean the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with a specific virus in the Field. For example HIV Indication means the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with Human Immunodeficiency Virus (HIV) and HCV Indication means prevention, treatment or diagnosis of a condition, infection or a disease caused by or associated with Hepatitis C Virus (HCV).

Field of Use
Field means any and all anti-viral uses, including but not limited to prophylaxis, diagnosis or treatment of a condition, infection or disease associated with a virus, except the Field specifically excludes any anti-viral use associated with (a) the following DNA virus families  poxviridae, polyomaviridae, papillomaviridae, adenoviridae, and parvoviridae; and (b) all RNA viruses except for the following RNA virus families, which are specifically included in the Field  retroviridiae (for example HIV as defined below), flaviviridae (for example HCV as defined below), orthomyxoviridae, paramyxoviridae, and coronaviridae. In the event that Licensee terminates the Sponsored Research Agreement (“SRA”), a copy of which is attached as Appendix J, pursuant to paragraph 16(d) of the SRA, the Field of this License Agreement shall automatically be amended to exclude HCV.

IPSCIO Record ID: 243481

License Grant
The Licensor of the United Kingdom and Licensee wish to collaborate on the discovery and development of Hepatitis C inhibitors which act through the viral replicase enzyme.

The United Kingdom Licensor grants an exclusive license, under the Licensor Patents and under Licensor Know-How, to make, have made, use, import, offer to sell, sell and have sold Products in the Territory. Licensor also grants the right to sublicense.

This agreement also includes a non-exclusive grant back to the Licensor.

License Property
The Licensors library consists of Millions of compounds for potential use in high throughput screening are available for purchase from commercial suppliers.  Licensor has used state-of-the-art molecular design software to analyse these commercial compound libraries both for chemical diversity and drug potential, which are critical parameters in developing novel lead compounds. On the basis of these analyses, Licensor has purchased a unique set of chemically diverse, drug-like molecules. Licensors library has also been selected to avoid poor chemical starting points for drug design. The Licensor Library currently contains approximately 50,000 compounds and all of these will be evaluated in the hepC polymerase primary assay.  Compounds which demonstrate activity in the primary assay, will be defined as selected compounds. All other compounds will remain proprietary to Licensor.

Licensee sourced compounds mean compounds supplied by Licensee to Licensor for the purpose of screening by Licensor pursuant to the Research Program in the HCV Replicase Assay.

Field of Use
The primary assay to be used in the research program will determine the inhibitory effects of compounds from Licensor or Licensee libraries on a truncated form of the Hepatitis C RNA polymerase.

The Parties wish to collaborate on the discovery and development of Hepatitis C inhibitors which act through the viral replicase enzyme.

IPSCIO Record ID: 277105

License Grant
For outside the licensed field, Licensor grants a worldwide, non-exclusive, and sublicenseable right and license to practice Licensors rights in Joint Collaboration Patent Rights to make, have made, import, promote, market, distribute or sell Licensee Products outside the Licensed Field.

This agreement contains both exclusive and non-exclusive grants between the parties.

License Property
The Patent Rights and Know-How are pertaining to the PADRE® Technology.

Licensed Product shall mean a therapeutic or prophylactic vaccine the manufacture. use or sale of which, but for any license granted to Licensee herein, would infringe a Valid Claim of one or more Licensor Patent Rights or one or more Collaboration Patent Rights, or was developed or manufactured using Licensor Know-How.

PADRE® Technology shall mean a family of immunostimulatory molecules which when combined with cytotoxic T cell epitopes increase the magnitude and duration of the immune response.

Field of Use
Licensed Field shall mean the research, development and commercialization of Licensed Products for treating or preventing diseases associated with the following viruses HPV. HBV and HCV.  HBV shall mean Hepatitis B Virus.  HCV shall mean Hepatitis C Virus.  HPV shall mean Human Papilloma Virus.  First HPV Indication shall mean treatment or prevention of cervical dysplasias and neoplasia.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.